Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vigil (FANG) vaccine in advanced melanoma
NCT01453361Phase 2Terminated
- Sponsor
- Gradalis, Inc.
- Start
- Oct 2011
- Primary completion
- Mar 2016
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA), Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemogenovatucel-T in melanoma, sponsored by Gradalis, Inc. Primary endpoint: Enzyme-Linked ImmunoSorbent Spot up to 12 months. Started Oct 2011; status: terminated.
02
Drugs
gemogenovatucel-T
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01453361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01453361.